Subscribe To
Mannkind’s inhaled clofazimine will advance to an adaptive phase 2/3 study for potential treatment of rare lung disease
Direct delivery of clofazimine to the lungs may provide a treatment option for nontuberculous mycobacterial (NTM) lung disease that potentially overco...
January 23, 2023, 11:05 am
Pulmatrix to present data on pur1800 at the annual meeting of the american academy of allergy, asthma and immunology
LEXINGTON, Mass. , Jan. 23, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative...
January 23, 2023, 9:05 am
Beyond air® schedules third fiscal quarter 2023 financial results conference call and webcast
Call scheduled for Thursday, February 9th at 4:30 pm Eastern Time GARDEN CITY, N.Y., Jan. 17, 2023 (GLOBE NEWSWIRE) — Beyond Air, Inc. (NASDAQ: XAIR...
January 17, 2023, 9:05 pm
Baxter - steak at hamburger prices
Baxter International Inc. ( BAX , Financial) is a health care company that offers a wide range of products and services such as dialysis treatments, I...
January 6, 2023, 11:05 am
Asthma and copd drugs market size to hit usd 34,374.23 million by 2030 at 4.20% cagr – report by market research future (mrfr)
Asthma and COPD Drugs Market Trends, Growth and Insights by Disease (COPD and Asthma), Product (Long-Term Asthma Control Medications, Quick Relief Med...
December 15, 2022, 12:45 am
China 'definitely' needs 2nd covid booster dose: cansino biologics ceo
Yu Xuefeng, chief executive officer of CanSino Biologics Inc., a Tianjin, China-based drugmaker that's rolling out a vaccine that can be...
December 6, 2022, 11:47 pm
Mannkind to present two posters at 22nd annual diabetes technology meeting
WESTLAKE VILLAGE, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercializ...
November 10, 2022, 6:05 am
Mannkind corporation participating at upcoming conferences
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., May 09, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the developmen...
May 9, 2022, 6:00 am
Nrx pharma says i-spy study of inhaled zyesami in critical covid-19 stopped
Quantum Leap Healthcare Collaborative (QLHC) announced that the nebulized form of NRx Pharmaceuticals Inc's (NASDAQ: NRXP) Zyesami (Aviptadil) in th...
March 31, 2022, 1:33 pm
Mannkind corporation to participate in the lytham partners spring 2022 investor conference
DANBURY, Conn., March 28, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of<...
March 28, 2022, 6:05 am
Mannkind corporation to participate in svb leerink 2022 global healthcare conference
DANBURY, Conn., Feb. 10, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of...
February 10, 2022, 6:05 am
Mannkind corporation to participate in svb leerink 2022 global healthcare conference
DANBURY, Conn., Feb. 10, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of...
February 10, 2022, 6:05 am
Mannkind corporation to participate in svb leerink 2022 global healthcare conference
DANBURY, Conn., Feb. 10, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of...
February 10, 2022, 6:05 am
Verona pharma: first inhaled product candidate combining anti-inflammatory and bronchodilator effects, a potential blockbuster
he company's lead product candidate is Ensifentrine, an inhaled PDE3, and PDE4 inhibitor, which is bein...
February 3, 2022, 7:00 pm
Verona pharma: first inhaled product candidate combining anti-inflammatory and bronchodilator effects, a potential blockbuster
he company's lead product candidate is Ensifentrine, an inhaled PDE3, and PDE4 inhibitor, which is bein...
February 3, 2022, 7:00 pm
Verona pharma: first inhaled product candidate combining anti-inflammatory and bronchodilator effects, a potential blockbuster
he company's lead product candidate is Ensifentrine, an inhaled PDE3, and PDE4 inhibitor, which is bein...
February 3, 2022, 7:00 pm